Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases  from Suzhou Sinovent and SinoMab Bio in a $561 million deal. The candidate is a next-gen covalent reversible BTK inhibitor that has shown high selectivity, excellent pharmacokinetics, robust target engagement and a good safety profile in a Phase I China trial conducted by SinoMab. Everest will pay Sinovent and SinoMab $12 million upfront and up to $549 million in milestones, plus royalties. Everest will own full manufacturing rights along with development and commercialization rights. More details.... Stock Symbols: (HK 1952) (HK: 3681) Share this with colleagues: // //